CureVac Financial Statements From 2010 to 2024

CVAC Stock  USD 2.44  0.13  5.06%   
CureVac NV financial statements provide useful quarterly and yearly information to potential CureVac NV investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on CureVac NV financial statements helps investors assess CureVac NV's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting CureVac NV's valuation are summarized below:
Gross Profit
-91.5 M
Market Capitalization
575.5 M
Enterprise Value Revenue
4.6573
Revenue
42.9 M
Earnings Share
(1.56)
We have found one hundred twenty available fundamental signals for CureVac NV, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of CureVac NV's prevailing performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. As of April 19, 2024, Market Cap is expected to decline to about 1.2 B. In addition to that, Enterprise Value is expected to decline to about 671.8 M

CureVac NV Total Revenue

53.62 Million

Check CureVac NV financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CureVac main balance sheet or income statement drivers, such as Tax Provision of 70.3 K, Net Interest Income of 5.7 M or Interest Income of 13.6 M, as well as many exotic indicators such as Price To Sales Ratio of 17.32, Dividend Yield of 0.0 or PTB Ratio of 2.19. CureVac financial statements analysis is a perfect complement when working with CureVac NV Valuation or Volatility modules.
  
This module can also supplement CureVac NV's financial leverage analysis and stock options assessment as well as various CureVac NV Technical models . Check out the analysis of CureVac NV Correlation against competitors.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

CureVac NV Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets833 M989.5 M440.9 M
Slightly volatile
Other Current Liabilities69.9 M53.2 M36.4 M
Slightly volatile
Total Current Liabilities179.9 M179.7 M93.5 M
Slightly volatile
Other Liabilities198.2 M99.6 M108.6 M
Slightly volatile
Property Plant And Equipment Net145 M278 M96.4 M
Slightly volatile
Current Deferred Revenue58 M42.3 M27.4 M
Slightly volatile
Accounts Payable48.9 M78.5 M28.1 M
Slightly volatile
Cash590 M570.2 M267.5 M
Slightly volatile
Non Current Assets Total163.3 M317.9 M109.6 M
Slightly volatile
Non Currrent Assets Other1.1 M1.9 M529.7 K
Slightly volatile
Other Assets4.6 M2.7 M5.7 M
Slightly volatile
Cash And Short Term Investments601.6 M575.3 M293.1 M
Slightly volatile
Net Receivables47.6 M45.4 M15.5 M
Slightly volatile
Common Stock Total Equity26.1 M24.9 M8.2 M
Slightly volatile
Common Stock Shares Outstanding191.4 M217.4 M179.1 M
Slightly volatile
Short Term Investments3.8 MM25 M
Slightly volatile
Liabilities And Stockholders Equity833 M989.5 M440.9 M
Slightly volatile
Non Current Liabilities Total230.2 M196.6 M133.1 M
Slightly volatile
Inventory22.8 M27.6 M11.9 M
Slightly volatile
Other Current Assets5.8 M6.1 M9.3 M
Slightly volatile
Total Liabilities410.1 M376.3 M226.6 M
Slightly volatile
Deferred Long Term Liabilities258.2 K271.8 K672.5 K
Slightly volatile
Net Invested Capital437.2 M613.2 M219.6 M
Slightly volatile
Property Plant And Equipment Gross156.9 M297.5 M99.4 M
Slightly volatile
Total Current Assets669.7 M671.6 M331.3 M
Slightly volatile
Accumulated Other Comprehensive Income1.3 B2.1 B849.7 M
Slightly volatile
Capital Stock15.2 M26.9 M7.8 M
Slightly volatile
Non Current Liabilities Other16.2 K17.1 K593.1 K
Slightly volatile
Net Working Capital489.8 M492 M237.8 M
Slightly volatile
Short Term Debt3.1 M5.7 M1.6 M
Slightly volatile
Intangible Assets12.9 M22.2 M9.6 M
Slightly volatile
Common Stock15.2 M26.9 M7.8 M
Slightly volatile
Property Plant Equipment242 M230.5 M93.3 M
Slightly volatile
Short and Long Term Debt Total36 M37.9 M64.4 M
Slightly volatile
Long Term Debt52 M58.5 M63.7 M
Slightly volatile

CureVac NV Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income13.6 M12.9 M4.1 M
Slightly volatile
Depreciation And Amortization17.2 M30.3 M10.4 M
Slightly volatile
Interest Expense8.3 M7.4 M3.7 M
Slightly volatile
Selling General Administrative66.4 M78.4 M39.5 M
Slightly volatile
Selling And Marketing Expenses356.5 K375.3 KM
Slightly volatile
Total Revenue53.6 M42.9 M29.9 M
Slightly volatile
Other Operating Expenses262.9 M366 M167.3 M
Slightly volatile
Research Development217.7 M110 M115.9 M
Slightly volatile
Cost Of Revenue116 M150.8 M59.4 M
Slightly volatile
Total Operating Expenses197.8 M352 M121.4 M
Slightly volatile
Reconciled Depreciation14.5 M17.8 M8.2 M
Slightly volatile

CureVac NV Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow518.2 M540.9 M276.1 M
Slightly volatile
Depreciation14.5 M17.8 M8.2 M
Slightly volatile
Capital Expenditures65.4 M61.5 M36 M
Slightly volatile
End Period Cash Flow578.1 M471.4 M260.2 M
Slightly volatile
Other Cashflows From Investing Activities2.9 M3.7 M2.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio17.3218.23454
Slightly volatile
Days Sales Outstanding189246190
Very volatile
EV To Sales9.9610.49450
Slightly volatile
Inventory Turnover3.746.95.4772
Pretty Stable
Days Of Inventory On Hand51.9954.7382.7829
Pretty Stable
Payables Turnover2.783.12.2843
Slightly volatile
Sales General And Administrative To Revenue1.561.521.5243
Pretty Stable
Research And Ddevelopement To Revenue0.790.832.9636
Pretty Stable
Cash Per Share2.812.381.7014
Slightly volatile
Days Payables Outstanding165122187
Very volatile
Intangibles To Total Assets0.03320.04250.0415
Slightly volatile
Current Ratio2.663.362.8942
Slightly volatile
Receivables Turnover1.461.543.666
Pretty Stable
Graham Number5.858.234.0619
Slightly volatile
Revenue Per Share0.230.320.1721
Slightly volatile
Interest Debt Per Share0.210.220.1156
Slightly volatile
Debt To Assets0.05340.05620.055
Pretty Stable
Operating Cycle332300279
Pretty Stable
Days Of Payables Outstanding165122187
Very volatile
Ebt Per Ebit0.810.90.9702
Slightly volatile
Long Term Debt To Capitalization0.07110.07481.5164
Slightly volatile
Total Debt To Capitalization0.07990.08410.1704
Pretty Stable
Quick Ratio2.453.112.6716
Slightly volatile
Net Income Per E B T1.11.151.0169
Slightly volatile
Cash Ratio2.022.861.5731
Slightly volatile
Days Of Inventory Outstanding51.9954.7382.7829
Pretty Stable
Days Of Sales Outstanding189246190
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.921.191.1632
Slightly volatile
Fixed Asset Turnover0.290.250.3071
Pretty Stable
Debt Ratio0.05340.05620.055
Pretty Stable
Price Sales Ratio17.3218.23454
Slightly volatile
Asset Turnover0.09580.09010.096
Slightly volatile

CureVac NV Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.2 B1.2 BB
Slightly volatile
Enterprise Value671.8 M707.2 M6.7 B
Slightly volatile

CureVac Fundamental Market Drivers

Forward Price Earnings9.1659
Cash And Short Term Investments500.3 M

CureVac Upcoming Events

23rd of April 2024
Upcoming Quarterly Report
View
4th of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
23rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About CureVac NV Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include CureVac NV income statement, its balance sheet, and the statement of cash flows. CureVac NV investors use historical funamental indicators, such as CureVac NV's revenue or net income, to determine how well the company is positioned to perform in the future. Although CureVac NV investors may use each financial statement separately, they are all related. The changes in CureVac NV's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CureVac NV's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CureVac NV Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CureVac NV. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue42.3 M58 M
Total Revenue42.9 M53.6 M
Cost Of Revenue150.8 M116 M
Stock Based Compensation To Revenue 0.16  0.30 
Sales General And Administrative To Revenue 1.52  1.56 
Research And Ddevelopement To Revenue 0.83  0.79 
Capex To Revenue(1.59)(1.67)
Revenue Per Share 0.32  0.23 
Ebit Per Revenue(3.33)(3.50)

Pair Trading with CureVac NV

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CureVac NV position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CureVac NV will appreciate offsetting losses from the drop in the long position's value.

Moving together with CureVac Stock

  0.79JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr

Moving against CureVac Stock

  0.77NUVB Nuvation Bio Financial Report 2nd of May 2024 PairCorr
  0.43JSPRW Jasper TherapeuticsPairCorr
  0.42IOVA Iovance Biotherapeutics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to CureVac NV could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CureVac NV when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CureVac NV - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CureVac NV to buy it.
The correlation of CureVac NV is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CureVac NV moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CureVac NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CureVac NV can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:
Check out the analysis of CureVac NV Correlation against competitors.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.
Note that the CureVac NV information on this page should be used as a complementary analysis to other CureVac NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for CureVac Stock analysis

When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is CureVac NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.56)
Revenue Per Share
0.201
Quarterly Revenue Growth
0.47
Return On Assets
(0.18)
Return On Equity
(0.49)
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.